Research programme: adenosine receptor modulators - Palobiofarma
Alternative Names: e compound; PBF 1350; PBF 1472; PBF 1509; PBF-1250; PBF-695; PBF-942Latest Information Update: 02 Jan 2023
At a glance
- Originator Palobiofarma
- Class
- Mechanism of Action Adenosine A1 receptor agonists; Adenosine A1 receptor antagonists; Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists; Adenosine A3 receptor antagonists; Phosphodiesterase 10A inhibitors; Plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Atrial fibrillation; Glaucoma; Psychiatric disorders
Highest Development Phases
- Discontinued Atrial fibrillation; Glaucoma; Idiopathic thrombocytopenic purpura; IgA nephropathy; Lung cancer; Psychiatric disorders
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Idiopathic thrombocytopenic purpura in Spain
- 28 Feb 2020 No recent reports of development identified for research development in IgA-nephropathy in Spain
- 28 Feb 2020 No recent reports of development identified for research development in Lung-cancer in Spain